HUTCHMED (NASDAQ:HCM) Shares Gap Up – Still a Buy?

HUTCHMED (China) Limited (NASDAQ:HCM) gapped up before the market opened on Friday . The stock had previously closed at $13.32, but opened at $13.99. HUTCHMED shares last traded at $14.21, with a volume of 21,761 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Monday, November 18th.

HUTCHMED Stock Up 6.6 %

The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The stock’s fifty day moving average is $15.88 and its two-hundred day moving average is $17.66.

Institutional Trading of HUTCHMED

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC boosted its holdings in HUTCHMED by 362.2% during the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock worth $1,305,000 after buying an additional 49,366 shares in the last quarter. State Street Corp boosted its stake in HUTCHMED by 0.9% in the 3rd quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after purchasing an additional 3,078 shares during the period. Rhumbline Advisers boosted its stake in HUTCHMED by 8.1% in the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock worth $129,000 after purchasing an additional 564 shares during the period. M&G PLC boosted its stake in HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company’s stock worth $5,345,000 after purchasing an additional 132,333 shares during the period. Finally, Blue Trust Inc. boosted its stake in HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after purchasing an additional 3,057 shares during the period. 8.82% of the stock is currently owned by institutional investors.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.